Cassava’s Alzheimer’s Drug Fails In First Phase III, Second Pivotal Trial Stopped

SEC Settlement Overhang Remains

 
• By Mandy Jackson
  
Cassava likely has reached the end of the road with simufilam (Shutterstock)

More from Clinical Trials

More from Scrip